Akero Therapeutics, INC Form 4 insider transactions

Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported the acquisition of shares through the company's employee stock purchase plan and the sale of shares under a pre-arranged trading plan.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 2,516 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Catriona Yale, Chief Development Officer of Akero Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

William Richard White, CFO of Akero Therapeutics, sold 2,831 shares of common stock on June 11, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, sold 2,380 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Akero Therapeutics CEO Andrew Cheng sold 7,894 shares of common stock on June 11, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director Yuan Xu reports acquisition of stock options in Akero Therapeutics.

Director Graham G. Walmsley acquired 26,000 stock options in Akero Therapeutics, Inc. on June 8, 2024.

Director Mark T Iwicki acquired 26,000 stock options in Akero Therapeutics, Inc. on June 8, 2024, according to a recent SEC filing.

Director Tomas J. Heyman acquired 26,000 stock options in Akero Therapeutics, Inc. on June 8, 2024.

Jane Henderson, a director of Akero Therapeutics, Inc., reported the acquisition of stock options on June 8, 2024.

Director Seth Loring Harrison acquired 26,000 stock options in Akero Therapeutics, Inc. on June 8, 2024.

Director Judy Chou acquired 26,000 stock options in Akero Therapeutics, Inc. on June 8, 2024.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 5,000 shares of common stock on June 3, 2024, at a weighted average price of $19.288 per share.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 5,000 shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics, received stock options for 225,000 shares on April 29, 2024.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, executed sales of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Catriona Yale, Chief Development Officer of Akero Therapeutics, sold 723 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

William Richard White, CFO of Akero Therapeutics, sold 724 shares of common stock on March 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Akero Therapeutics CEO Andrew Cheng sold 1,969 shares of common stock on March 13, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 651 shares of common stock on March 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, sold 619 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Akero Therapeutics' CEO, Andrew Cheng, exercised stock options and sold shares of common stock on March 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Catriona Yale, Chief Development Officer of Akero Therapeutics, executed stock options and sold shares according to a pre-arranged trading plan.

Jonathan Young, COO of Akero Therapeutics, exercised stock options and acquired shares, increasing his total holdings.